Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in relapsed/refractory follicular lymphoma without EZH2 mutation
NCT06068881Phase 2Withdrawn
- Sponsor
- Epizyme, Inc.
- Start
- Sep 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in follicular lymphoma (FL), sponsored by Epizyme, Inc. Primary endpoint: Objective Response Rate up to 5 years. Planned start Sep 2025; status: withdrawn.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06068881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068881.